Tag: muscle-invasive bladder cancer therapy

Home / muscle-invasive bladder cancer therapy

Categories

Durvalumab is approved by the USFDA for muscle invasive bladder cancer

On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) to be used with gemcitabine and cisplatin as a first treatment, followed by durvalumab alone as a follow-...
muscle-invasive-bladder-cancer-therapy

Scan the code